# Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer

> **NCT07533266** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 360 (estimated)

## Conditions studied

- NSAID (Non-Steroidal Anti-Inflammatory Drug)

## Interventions

- **DRUG:** Fexuprazan 20mg
- **DRUG:** Lansoprazole 15 mg placebo
- **DRUG:** Lansoprazole 15 mg
- **DRUG:** Fexuprazan 20mg placebo

## Key facts

- **NCT ID:** NCT07533266
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07533266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07533266, "Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07533266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*